BET inhibitors combined with chemotherapy synergistically inhibit the growth of NSCLC cells-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

BET inhibitors combined with chemotherapy synergistically inhibit the growth of NSCLC cells

Published:2021-03-22 Issue:5 Volume:45 Page:
ISSN:1021-335X
Container-title:Oncology Reports
language:
Short-container-title:Oncol Rep

Author:

Zhou Xiao¹,Sun Tong²,Meng Yuting³,Luo Juan¹,Chen Jun¹,Xia Bo¹,Zhang Zuhao³,Cheng Zhixiang¹,Wang Xuerong²

Affiliation:

1. Department of Pain Management, The Second Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu 210011, P.R. China

2. Key Laboratory of Human Functional Genomics of Jiangsu Province, Nanjing Medical University, Nanjing, Jiangsu 211100, P.R. China

3. Department of Pharmacology, Nanjing Medical University, Nanjing, Jiangsu 210029, P.R. China

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology,General Medicine

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pathogenic role of super-enhancers as potential therapeutic targets in lung cancer;Frontiers in Pharmacology;2024-04-12

2. Synergistic Sensitization of High-Grade Serous Ovarian Cancer Cells Lacking Caspase-8 Expression to Chemotherapeutics Using Combinations of Small-Molecule BRD4 and CDK9 Inhibitors;Cancers;2023-12-24

3. Bromodomain‐containing protein 4 inhibition improves the efficacy of cisplatin and radiotherapy in oral squamous cell carcinoma by suppressing programmed cell death‐ligand 1 expression;Basic & Clinical Pharmacology & Toxicology;2023-12-06

4. Bromodomain inhibitor i-BET858 triggers a unique transcriptional response coupled to enhanced DNA damage, cell cycle arrest and apoptosis in high-grade ovarian carcinoma cells;Clinical Epigenetics;2023-04-15

5. BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications;Molecules;2023-03-29

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3